Help
Subscribe


GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy

 22 February 2018

Advanced search
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Monitoring intestinal inflammation using fecal calprotectin

Calprotectin could be suitable as a marker for assessing and monitoring disease activity in inflammatory bowel disease, as well as in screening for carcinoma and bowel disease in the general population, finds a study in the European Journal of Gastroenterology and Hepatology.

News image

fiogf49gjkf04

Calprotectin is a neutrophil granulocyte-derived protein that has been found in increased levels in plasma, cerebrospinal fluid, synovial fluid, saliva and urine following infection, inflammation and malignant disease in relevant organs, following activation of monocytes and neutrophil granulocytes.

The protein is also excreted in feces, in which it remains very stable, and so fecal calprotectin concentrations may provide an easy test for assessing infection, disease or inflammatory activity in the alimentary tract.

Calprotectin is known to be an inhibitor of zinc-dependent enzymes that, by competing for zinc, can kill microbes and induce apoptosis in both normal and malignant cells.

Zinc-dependent metalloproteinases are needed for activation of cytokines like tumor necrosis factor alpha and for invasive growth of tumors and so it is thought that calprotectin may therefore participate in the regulation of inflammatory processes and inhibit cancer cell proliferation.

However, it is possible that elevated concentrations of this protein may also induce cell and tissue damage.

It is known that there is accumulation of neutrophils at sites of active inflammatory bowel disease (IBD), leading to the possibility that cytotoxic levels of calprotectin may be reached locally and that this protein may also play an active role in IBD, in addition to being a useful fecal marker.

Therefore, researchers from the departments of Gastroenterology and Clinical Biochemistry at the North Manchester General Hospital in Manchester, England, have assessed the potential of measuring calprotectin in feces as a method of screening for alimentary inflammation and neoplasia.

Consented patients attending for routine endoscopy were requested to provide feces.

Of the initial 30 patients enrolled, 17 provided feces before and 1 week after endoscopy.

A further 116 patients with planned endoscopy provided feces prior to undergoing endoscopy.

The group comprised 43 patients with upper gastrointestinal lesions, 7 patients with IBD, a further 7 patients with irritable bowel disease, 31 patients with colonic disorders, and 28 normal people.

A final 18 patients with known inflammatory bowel disease (7 patients), gastric carcinoma (1 patient), colorectal cancer (8 patients) and colorectal adenoma (2 patients) also had stool samples analyzed.

Fecal calprotectin:
Elevated in inflammation and cancer
European Journal of Gastroenterology & Hepatology

Feces were analyzed using enzyme-linked immunosorbent assay (ELISA) techniques.

Following such analysis, no definite differences between pre- and post-endoscopy calprotectin were found.

Analyses of samples from subsequent patients were therefore carried out on pre-endoscopy feces only, as this was considered preferable.

Upper-gastrointestinal disorders showed little difference in calprotectin levels: Barrett's esophagus (median 6.8 mg/l), gastric ulcer (median 6.5 mg/l) or gastritis/duodenitis (median 5.2 mg/l).

However, these were all higher than the median calprotectin level of normal subjects (4.5 mg/l).

The esophageal and gastric carcinoma median was elevated significantly at 30 mg/l, while inflammatory bowel disease was also associated with marked elevation (Crohn's disease, 31.2 mg/l; ulcerative colitis, 116.2 mg/l).

Colorectal polyps (median 3.7 mg/l) and adenoma (median 3.8 mg/l) showed no elevated levels in contrast to colorectal carcinoma (median 53.4 mg/l).

The elevated calprotectin in IBD and colorectal carcinoma combined gave a sensitivity of 81.8% and a specificity of 73.2%.

"Calprotectin levels are elevated in inflammation and cancer but are not helpful in differentiating between these disorders," commented Dr Christopher B. Summerton, one of the study authors, adding, "In our series, calprotectin was not elevated in colonic polyps or adenomata."

"However," he continued, "Calprotectin could be helpful as a screening method in a general gastroenterology population for inflammatory bowel disease and those with carcinoma, as well as assessing and monitoring disease activity in inflammatory bowel disease."

Eur J Gastroenterol Hepatol 2002; 14(8): 841-845
06 August 2002

Go to top of page Email this page Email this page to a colleague

 22 February 2018 
Outcomes with Crohn’s after infliximab withdrawal
 22 February 2018 
Elderly onset of IBD

 22 February 2018 
Autophagy enhancers
 21 February 2018 
Management of hemorrhoids in the USA
 21 February 2018 
Adalimumab and infliximab in biologic-naïve Crohn's
 21 February 2018 
Cystic fibrosis and colorectal cancer
 20 February 2018 
Complications and surveillance colonoscopies
 20 February 2018 
Treatment algorithm for polyp cancers
 20 February 2018 
Predictors of postoperative infection in Crohn's
 19 February 2018 
Screening colonoscopy in the right and left colon
 19 February 2018 
NAFLD prevalence in the USA
 19 February 2018 
Fructans in children with IBS

 16 February 2018 
Inflammatory bowel diseases are global diseases
 16 February 2018 
Undetected celiac in the elderly
 16 February 2018 
Fructans induce non-celiac gluten sensitivity
 15 February 2018 
NSAIDS and GI damage
 15 February 2018 
Oral direct-acting antiviral treatment for Hep C virus genotype 1
 15 February 2018 
Primary vs secondary surgery for the presence of lymph node metastasis
 14 February 2018 
Predicting adenoma detection rate
 14 February 2018 
Normal bowel frequency characterization in the USA 
 13 February 2018 
Personalising treatment options for IBS
 13 February 2018 
Prebiotics improve endothelial dysfunction
 13 February 2018 
Diagnostic criteria for a Rome IV functional gastrointestinal disorders
 12 February 2018 
Visceral hypersensitivity and functional GI disorders
 12 February 2018 
Depression and aggressive IBD
 12 February 2018 
Variability in interpretation of endoscopic findings impacts patient management
 09 February 2018 
Treatment of choice for anastomotic stricture in IBD
 09 February 2018 
PRO measurement information system 
 09 February 2018 
Overall disease severity indices for IBD
 08 February 2018 
Prediction of endoscopically active disease

 08 February 2018 
Steroid-refractory acute severe ulcerative colitis
 08 February 2018 
Decision aid used by IBD patients
 07 February 2018 
Ursodeoxycholic acid combined with bezafibrate for itching
 07 February 2018 
Change in microbiome in gastritis vs gastric carcinoma
 07 February 2018 
Colorectal cancer and primary sclerosing cholangitis-IBD
 06 February 2018 
Risk of death after liver transplantation
 06 February 2018 
Crohn’s disease vs refractory pouchitis
 06 February 2018 
Support for functional dyspepsia symptom diary
 05 February 2018 
Helicobacter spp influence on GI tract 
 05 February 2018 
No link found between severe reflux and all-cause mortality 
 05 February 2018 
Psychological distress in PPI non-responders
 02 February 2018 
Assessing psychosexual impact of IBD
 02 February 2018 
Decrease in overall mortality with cholera vaccination
 02 February 2018 
Diagnostic performance of fecal immunochemical tests
 01 February 2018 
Screening frequency with family histories of colorectal cancer
 01 February 2018 
IBD and sport participation
 01 February 2018 
Life with a stoma 
 31 January 2018 
Aprepitant and gastroparesis 
 31 January 2018 
Anesthesia risk in colonoscopy
 31 January 2018 
GED-0301 for Crohn's Disease
 30 January 2018 
Intestinal dysbiosis and allergic diseases in infants
 30 January 2018 
Fructans and IBS symptoms in children
 29 January 2018 
Dosing calculator for therapy optimization in IBD
 29 January 2018 
Glecaprevir–pibrentasvir for in HCV
 29 January 2018 
Food allergen injections in eosinophilic esophagitis
 29 January 2018 
Reliability of the IBD index
 26 January 2018 
Tofacitinib vs biological therapies for ulcerative colitis
 26 January 2018 
Optimizing selection of biologics in IBD
 26 January 2018 
Nutritional risk and laparoscopic-assisted gastrectomy outcomes
 25 January 2018 
Patient-reported outcome measure for functional dyspepsia

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2018 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us